-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say. Read more…
Recent articles
Get the latest Long COVID news and commentary
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Check out our weekly podcast, Still Here
Spotify
Apple Podcasts
PocketCasts
iHeartRadio
RSSTrending
Policy & Advocacy
-
Sen. Bernie Sanders seeks feedback on $10 billion “moonshot” for Long Covid
-
Photo essay: Long Covid advocates gather in DC for demonstration
-
Sen. Bernie Sanders introduces resolution to formalize Long Covid Awareness Day
-
How mask blocs are keeping communities safe with neglected government stockpiles
-
It’s “all hands on deck” for Long Covid Awareness Day as the CDC ignores Long Covid in new guidance
-
Q&A: Dr. Ian Simon on his plans for the HHS Office of Long Covid Research and Practice
Science
Covid-19
Health
-
We talked to a veteran lawyer about applying for disability insurance with Long COVID and ME
-
The trouble with recovery stories
-
Solange Knowles thanks chronic illness community, shares POTS, MCAS, and Sjögren’s diagnoses
-
New Long COVID and complex disease center at Mount Sinai set to be a leader in research, clinical care
-
Filmmaker Jesse Ridgway shares experience with Long COVID with millions of followers
-
Tinu Abayomi-Paul, writer, disability advocate, and person with Long COVID, dies at 52
-
“Perfect storm” of criminalization: Analyzing mask bans
-
As a doctor, I’m disappointed in my colleagues for ignoring Long COVID. I made a resource to educate them and the public.
-
Even as a former executive assistant, managing care for Long COVID is a full-time job
-
In South Africa, Long Covid is an afterthought to Tuberculosis